ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: 24 years Male

Specimen Collected: 12-Aug-24 11:26

HIV-1 Quant with Reflex to Genotype | **Received: 12-Aug-24 11:26** **Report/Verified: 12-Aug-24 11:27**

Procedure	Result	Units	Reference Interval
HIV-1 Qnt by NAAT (copies/mL)	90000	cpy/mL	
HIV-1 Qnt by NAAT (log copies/mL)	4.95 f1	log cpy/mL	
HIV-1 Qnt by NAAT Interp	**Detected** * i1		[Not Detected]

HIV-1 Drug Resistance by NGS | **Received: 12-Aug-24 11:26** **Report/Verified: 12-Aug-24 11:27**

Procedure	Result	Units	Reference Interval
HIV-1 Drug Resistance by NGS	See Note i2		
EER HIV-1 Drug Resistance by NGS	See Note		

Result Footnote

f1: HIV-1 Qnt by NAAT (log copies/mL)

HIV-1 Drug Resistance by Next Generation Sequencing will be added.

Test Information

i1: HIV-1 Qnt by NAAT Interp

INTERPRETIVE INFORMATION: HIV-1 by Quantitative NAAT, Plasma

The quantitative range of this assay is 1.30-7.00 log copies/mL (20-10,000,000 copies/mL).

A result of "Not Detected" does not rule out the presence of inhibitors or HIV-1 RNA concentration below the level of detection of the test. Care should be taken in the interpretation of any single viral load determination.

This test is intended for use in conjunction with clinical presentation and other laboratory markers for the clinical management of HIV-1 infected patients. The test can be used to assess patient prognosis by measuring the baseline HIV-1 level or to monitor the effects of antiretroviral therapy by measuring changes in HIV-1 RNA levels during the course of antiretroviral treatment.

This assay should not be used for blood donor screening, associated reentry protocols, or for screening human cell-, tissue-, and cellular tissue-based products (HCT/P).

i2: HIV-1 Drug Resistance by NGS

INTERPRETIVE INFORMATION: HIV-1 Drug Resistance by NGS

This assay predicts HIV-1 resistance to protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and integrase inhibitors. The protease gene, integrase gene and the reverse transcriptase gene of the viral genome are sequenced using Next Generation Sequencing. Drug resistance is assigned using the Stanford hivdb database.

Test Information

i2: HIV-1 Drug Resistance by NGS

This test should be used in conjunction with clinical presentation and other laboratory markers. A patient's response to therapy depends on multiple factors, including patient adherence, percentage of resistant virus population, dosing, and drug pharmacology issues.

This test detects populations down to 10 percent of the total population which may account for resistance interpretation differences between methods. Some insertions or deletions may be difficult to detect using this software.

This test was developed, and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.